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1. Introduction 
The term inflammatory bowel disease (IBD) is frequently used in the medical literature to 
define a set of diseases involving the digestive tract, particularly the small and the large 
intestine. The major IBDs are Crohn’s Disease (CD) and ulcerative colitis (UC). 
Ulcerative colitis is a chronic inflammatory disease characterized by diffuse mucosal 
inflammation limited to the colon. UC affects 500,000 individuals in the United States with 
an incidence of 12 per 100,000 per year. The lifetime risk of a severe exacerbation of UC 
requiring hospitalization is 15%. Patients with extensive disease (macroscopic disease 
proximal to the splenic flexure) are more likely to develop acute severe colitis. 
Approximately 4% to 9% of UC patients will require colectomy within the first year of 
diagnosis; the risk of colectomy following that is 1% per year. The vast majority of UC 
patients will require medical therapy throughout their lifetime.  
Ulcerative colitis, usually, involves the rectum at presentation and may extend proximally in 
a symmetrical, circumferential, and continuous pattern to involve parts or all of the large 
intestine. The disease course of UC is characterized by exacerbations and remissions, which 
may occur spontaneously or in response to treatment changes, superimposed infection. The 
diagnosis of inflammatory bowel disease is based on clinical history in combination with the 
results of various tests, once a single pathognomonic test allowing for a diagnostic definition 
is not available. Hence, the following can be cited: radiology, laboratory and hematological 
tests, and endoscopy combined with histology in particular.1-3  
With this respect, endoscopy has revolutionized the management of patients with IBD by 
increasingly enabling the identification and study of lesions. Some more recent advances in 
endoscopic techniques can be cited, such as double-balloon enteroscopy and the capsule 
endoscopy, which allow for evaluating areas of the small intestine that have not been 
thoroughly studied to this date, in addition to digital chromoendoscopy. 
Improvement in IBD diagnostic capacity has direct implications in the diagnosis and follow-
up of patients that have or are suspected to have IBD as well as in better understanding their 
pathogenesis, which consequently influences treatment.  
Great changes have occurred in IBD treatment and management in the last few decades due 
to the introduction of biological agents in its therapeutic arsenal. Biological therapy, 
represented by its major drugs – anti-TNF antibodies – has rapidly become the top of a 
mountain whose base is represented by other drugs that have been used in the treatment of 
inflammatory bowel disease for several decades.  
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These new drugs directly interfere with the individual’s immune response by decreasing the 
activation of T cells and inducing apoptosis of defense cells, thus controlling this complex 
mechanism which is still not fully known and triggers diseases such as ulcerative colitis and 
Crohn’s Disease. 
Some time ago, it was believed that the most important objective in treatment would be the 
patient’s clinical remission, normally based on symptom and sign scores, in CD (CDAI – 
Crohn’s disease activity index < 150 points), and in UC (Mayo Score < 5 points). However, 
after the advent of biological therapy, which induces healing of the inflamed intestinal 
mucosa, such objectives have changed, that is, in addition to seeking sustained clinical 
remission, mucosal healing should also be sought. 
Due to these characteristics and to the fact that such healing can be maintained for long 
periods, it is believed that the development and prognosis of IBD will also change. 
As previously pointed out, mucosal healing is one of the objectives of clinical trials and of 
daily clinical practice. For this reason, endoscopy, and colonoscopy in particular, assumes a 
major role in these patients’ follow-up by enabling the direct visualization of the mucosa as 
well as the removal of fragments for histological analysis. 
2. Indications 
The diagnosis of UC can be suggested initially by sigmoidoscopy in great number of cases 
during first attack of UC, fewest biopsies usually are sufficient to confirm the diagnosis and 
indicate the initial therapy. In patients with diarrhea, mucus, active and flares, this exam can 
be performed in unprepared bowel so the earliest signs of UC can be detected; other reason 
to do the sigmoidoscopy without bowel prep is to decrease the hyperemia that is often 
present after enemas.  
In this active fase, colonoscopy is not recommended for fear of perforation and the risk of 
cause great distention in colon. Only after this acute and active fase the colonoscopy can be 
performed to establish the extent of the disease and to exclude other disease and Crohn's 
disease.  
The initial aim points in colonoscopy are to evaluate both the extension and intensity of UC. 
In a second moment, to evaluate the response to the treatment. Thus, the colonoscopy is 
useful to make the diagnosis, to follow the evolution and response and finally prevent 
colorectal cancer (displasia). 
The most recent studies confirm that the mucosal healing is the end point of treatment, so 
the indications of colonoscopy do not resume in diagnostic only. In TABLE 1, are the most 
important indications of colonoscopy in UC.  
 
Acute Sub acute chronic 
Diagnosis Extension Treatment response 
Biopsy Intensity Displasia surveillance 
Differential diagnosis Biopsy Cancer surveillance 
 Treatment response  
Table 1. Indications of colonoscopy in ulcerative colitis 
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3. Bowel preparation 
Correct diagnostic of colonoscopy depends on the quality of the colonic preparation or 
cleansing. The ideal preparation should reliably empty the colon of fecal material in a rapid 
fashion and do not cause histological alteration or gross of the rectal and colonic mucosa.  
For patients, the preparation should not cause discomfort and shifts in electrolytes and 
fluids; those are the ideal bowel preparation, unfortunately none of the preparations 
available meet them. 
Recently, the American Society of Colon and Rectal Surgeons (ASCRS), the American 
Society for Gastrointestinal Endoscopy (ASGE), and the Society of American 
Gastrointestinal and Endoscopic Surgeons (SAGES) made a document: “A Consensus 
Document on Bowel Preparation Before Colonoscopy”. 4 Based on this document the 
recommendations are (grade of recommendation supported by evidence-based medicine): 
1. Diet- Dietary modifications, such as a clear liquid diet, alone are inadequate for 
colonoscopy. However, they have proven to be a beneficial adjunct to other mechanical 
cleansing methods (Grade IIB).  
2. Enemas - Use enemas in patients who present to endoscopy with a poor distal colon 
preparation and in patients with a defunctionalized distal colon. 
3. High-Volume Gut Lavage - Neither high-volume nor unbalanced solutions, such as 
mannitol, should be used for colonic preparation (Grade IA). In addition, caution 
should be exercised when using nasogastric tubes for the administration of any bowel 
preparation infusion (Grade VD). 
4. Rectal Pulsed Irrigation - administered immediately before the procedure combined 
with magnesium citrate given the evening before the procedure is a reasonable 
alternative to full-volume (4-liters) PEG in those individuals who cannot tolerate per 
oral administration of PEG (Grade IIB). 
5. PEG - Faster, more effective, and better-tolerated method for cleansing the colon than a 
restricted diet combined with cathartics, high-volume gut lavage, or mannitol/NaP 
(Grade IA). PEG is safer than osmotic laxatives/NaP for patients with electrolyte or 
fluid imbalances, such as renal or liver insufficiency, congestive heart failure, or liver 
failure and is, therefore, preferable in these patient groups (Grade IA). Divided-dose 
PEG regimens (2–3 liters given the night before the colonoscopy and 1–2 liters on the 
morning of procedure) are acceptable alternative regimens that enhance patient 
tolerance (Grade IIB). Cleansing preparations for colonoscopies performed in the 
afternoon should instruct that at least part of the PEG solution be given the morning 
before the procedure (Grade IIB). Enemas, bisacodyl, and metaclopramide as adjuncts 
to the full volume of PEG have not been demonstrated to improve colonic cleansing or 
patient tolerance and are, therefore, unnecessary (Grade IIB). 
6. NaP - Aqueous NaP colonic preparation is an equal alternative to PEG solutions except 
for pediatric and elderly patients, patients with bowel obstruction, and other structural 
intestinal disorders, gut dysmotility, renal or failure, congestive heart failure, or liver 
failure (Grade IA). Dosing of aqueous NaP should be 45 ml in divided doses, 10 to 12 
hours apart with one of the doses taken on the morning of the procedure (Grade IIB). 
Aqueous NaP is the preferable form of NaP at this time (Grade IIB). Apart from 
anecdotal reports, the addition of adjuncts to the standard NaP regimen has not 
demonstrated any dramatic effect on colonic cleansing preparation. Carbohydrate-
electrolyte solutions such as E-Lyte\ may improve safety and tolerability. 
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In those patients with possible underlying IBD, NaP preparations may cause mucosal 
abnormalities that mimic Crohn’s disease 5-7. However, the frequency of this problem is rare 
and may not mitigate against using NaP. This caveat is most important in the initial 
colonoscopic evaluation of patients with symptoms suspect for colitis.  
We may conclued that bowel preparation is safe for patients with UC and must be avoid in 
acute phases. 
4. Macroscopic characteristics of ulcerative colitis 
The macroscopic characteristic of UC is symmetrical and continuous inflammation, which 
begins in the rectum and extends proximally without interruption during the whole 
extension of the disease. When present, this aspect is easily made visible by colonoscopy.  
The figure 1 shows the initial endoscopic signs of UC: 
1. Reduction or loss of normal vascular patterns. 
2. Loss or distortion of vascular markings and relief, and, many times, this aspect may be 
the only endoscopic alteration in patients with UC in its quiescent phase 
3. Mucosal erythema and edema 
 
 
Fig. 1. Mucosal friability, loss of vascular pattern, eythema and edema 
As the disease progresses, the mucosal pattern changes, becomes extremely friable, and 
shows a granular aspect. The disease, then, enters the most severe phase, when the mucosa 
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is covered with yellowish and sometimes mucopurulent exudate, with intense ulceration of 
the adjacent mucosa. (FIGURE 2) Such exulceration and ulceration pattern is mainly 
characterized by a serpiginous, linear, dotted or annular aspect, or even an association of 
such aspects. As to size, they may vary from millimeters to centimeters, and may, at times, 
be deep, depending on the phase and inflammation intensity. 
 
 
Fig. 2. Colonic mucosa with intense ulceration covered with yellowish and mucopurulent 
exudates 
In the active and acute phase of the disease, a simple touch to these lesions by the 
instrument may cause bleeding due to mucosal friability. Another important aspect is that 
when such edema is intense and diffuse, it may lead to lumen narrowing. The differential 
diagnosis is made by adenomatous polyps, which can only be differentiated under 
microscopy. Another important differential diagnosis is made by CD. Crohn´s colitis 
endoscopic features includes: skip lesions(pathchy inflammation adjacent to normal 
mucosa), rectal sparing, aphtous ulcerations and cobblestone appearance of the mucosa due 
to the presence of deep linear ulcers. 
The inflammation/cicatrization process may lead to the onset of pseudopolyp images, 
which, in reality, are healthy mucosal areas amidst areas of an intense inflammatory 
process. (FIGURE 3) They can be characterized by endoscopy with small, bright and soft 
lesions that may develop to large pedunculated or sessile lesions. Also, they may be 
detected both in the acute and chronic phases of the disease and are largely suggestive of 
UC, showing the appearance of cobble-like shapes both by colonoscopy and opaque enema.  
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Other endoscopic aspects that can be made visible in patients with a chronic form of the 
disease are: 
1. Loss of normal haustration patterns  
2. Loss of normal colon architecture, with muscle hypertrophy 
3. Colon shortening  
4. Luminal diameter reduction 
5. Stenosis. In this case, the differential diagnosis is made from cancer. 
With this regard, some UC endoscopic activity scales have been developed with the purpose 
to classify and quantify such inflammatory activity in the colonic mucosa. The scale 
proposed and used by the Mayo Clinic is noteworthy.  
 
 
Table 2. Mayo score for ulcerative colitis * 
* from: Cima RR, Pemberton JH. Medical and surgical management of chronic ulcerative colitis. Arch 
Surg. 2005;140(3):300-10 
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Fig. 3. Pseudopolyps and colonic mucosal healing after infliximab treatment 
5. Histology 
The histological analysis of biopsy has the following aims: confirm the UC diagnosis, 
graduate the inflammatory response and third, confirm the presence of displasia or cancer.  
An early and accurate diagnosis is necessary. It is important to distinguish between IBD and 
acute self-limited colitis and a differential diagnosis between UC and CD. The 
histopathological diagnosis of UC should, therefore, be based on discriminating histological 
features which are sufficiently reproducible and suitable in routinely processed biopsy 
specimens. 
In cases where the clinical picture is unclear, the histomorphologic analysis often plays a 
pivotal role in determining the diagnosis and thus the management. By contrast, a biopsy 
analysis may be indeterminate, and thus the clinical progression of the disease must inform 
its treatment.  
Great changes have occurred in IBD treatment and management in the last few decades  
due to the introduction of biological agents in its therapeutic arsenal. Thus, mucosal  
healing is one of the objectives of clinical trials and of daily clinical practice. FIGURE 3  For 
this reason, colonoscopy assumes a major role in these patients’ follow-up by enabling the 
direct visualization of the mucosa as well as the removal of fragments for histological 
analysis.11-19 
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Fig. 4. Photomicrography of a colectomy specimen (pancolitis): we observe distortion of 
crypt architecture, inflammation of crypts (cryptitis) and crypt abcess (arrow) Courtesy of 
Prof. Dr. Marcus M. Matsushita, professor of the Pathology Department of the Hospital 
Universitário - ABHU, Medical School of the University of Marilia, São Paulo, Brazil. 
www.unimar.br 
6. Dysplasia and Colorectal Cancer (CRC) surveillance  
Dysplasia is considered the best marker of cancer risk in UC. The clinical management 
depends on the endoscopic and histological identification of dysplasia in mucosal biopsy 
specimens of the colon by pathologists with particular expertise in gastrointestinal 
disorders. The dysplasia can be divided in two groups: low-grade dysplasia (LGD) and 
high-grade dysplasia (HGD), not all patients with LGD will progress through detectable 
HGD. Patients with HGD have higher risk of progression to colorectal cancer.19  
Rubin and colleagues in Seattle showed that among a group of colectomy specimens 
obtained from UC patients, 33 biopsies per examination was the number of nontargeted 
biopsies required to exclude dysplasia with 90% confidence. 19   It has being reported that 
80% to 90% of UC patients with cancer have dysplasia when analyzed the colectomy 
specimen. However, colorectal cancer can develop in patients without a prior history of 
dysplasia. 14-15,19   
In a meta-analysis with 116 published studies, Eaden and colleagues found that the 
overall prevalence of CRC in any patient with UC is 3.7% which increases to 5.4% for 
those with pancolitis. 18  The cumulative risk for CRC of any patient with UC is 2% at 10 
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years, 8% at 20 years, and 18% at 30 years. Increasing duration of disease is as one of the 
most important risk factors for the development of cancer in UC, which is significant after 
9 years of disease and increases in subsequent years.13-19 The extension of the disease is 
also a risk factor for cancer. Most cancers arise in patients when the whole colon is 
affected (pancolitis). Patients with UC beyond the distal sigmoid and rectum are at 
increase risk of CRC and risk is intermediate in patients with left-sided disease and lower 
in patients with proctitis.14-19  
Recently, we have published the Brazilian consensus for management of IBD. Supported 
by evidence-based medicine, we recommend that the screening should be performed 
using colonoscopy every 3 years in the 2nd decade, every 2 years in the 3rd decade and 
yearly in the 4th decade of illness together with 4-quadrant biopsies of non-inflamed 
mucosal at every 10 cm of colon, in the whole colon in association with biopsies of 
suspected areas. 14  
7. Chromoendoscopy  
Because of the limitations of what could be seen with traditional colonoscopies emitting 
white light, adjunct techniques have been investigated in colitis and sporadic polyp 
surveillance practices that have the potential to enable endoscopists to better visualize the 
colorectal mucosa. It has being demonstrated a higher diagnostic accuracy for dysplasia 
diagnosis in biopsies targeted by chromoendoscopy when compared to biopsies obtained 
with standard colonoscopy.17  Chromo colonoscopy with biopsy of suspected area is a valid 
alternative to multiple biopsies.14 There are a stronger correlation between the endoscopic 
assessment of colonic inflammation and histopathologic findings. In this scenario, 
chromoendoscopy allow for the differentiation between nonneoplastic and neoplastic 
lesions with a sensitivity and specificity of 93%.  
It became apparent that adding an adjunct technique would enable us to identify more 
patients with dysplasia. Unfortunately, however, there are no longitudinal data showing 
that chromoendoscopy actually lessens either the incidence of dysplasia on follow-up 
colonoscopy or cancer-related morbidity or mortality. On the other hand, once this 
technique are inexpensive, safe, and relatively easy to perform, it should be have an 
important role in surveillance of dysplasia and cancer in UC patients.  
8. Narrow Band Imaging (NBI)  
Narrow band imaging (NBI) and Multi-Band Imaging (MBI)* are real-time, on-demand 
endoscopic imaging techniques designed to enhance visualization of the vascular network 
and surface texture of the mucosa in an effort to improve tissue characterization, 
differentiation, and diagnosis. 17 NBI and MBI were developed to be an alternative to 
chromoendoscopy. The techniques may allow contrast enhancement of tissue surface 
structures helping in the endoscopic diagnosis. In contrast, neither NBI nor MBI have being 
studied extensively as chromoendoscopy.17  
It has being reported in the literature that, in ulcerative colitis, the role of NBI is not as 
promising as observed in other scenarios. 8-10 On the other hand, in an uncontrolled study 
consisting of 46 patients with ulcerative colitis, the relative frequency of dysplasia was 
higher in areas of tortuous pattern (8%) than in those of honeycomb-like or villous pattern 
(0.4%), as seen under NBI with magnification. The tortuous pattern determined by NBI may 
be a clue for the identification of dysplasia during surveillance of UC. 9,16 
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